Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schram

Showing results (61-70 of 186) with videos related to

Pageof 19
Sort By:
Clinical Genitourinary Cancer|June 1, 2017
Genomic Characterization of Renal Medullary Carcinoma and Treatment OutcomesMaria I Carlo, Joshua Chaim, Sujata Patil, et al.
Future Oncology (London, England)|February 13, 2024
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring <i>NRG1</i> gene fusionsDong-Wan Kim, Alison M Schram, Antoine Hollebecque, et al.
Molecular Cancer Therapeutics|March 5, 2022
CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 HeterodimerizationLisa Werr, Dennis Plenker, Marcel A Dammert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2019
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation BurdenRyma Benayed, Michael Offin, Kerry Mullaney, et al.
Nature Communications|November 23, 2022
Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologiesYonina R Murciano-Goroff, Alison M Schram, Ezra Y Rosen, et al.
Cancer Research|January 16, 2019
Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase FusionsEmiliano Cocco, Jamal Benhamida, Sumit Middha, et al.
The New England Journal of Medicine|February 25, 2026
Phase 1 Study of Rezatapopt, a p53 Reactivator, in <i>TP53</i> Y220C-Mutated TumorsEcaterina E Dumbrava, Geoffrey I Shapiro, Aparna R Parikh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Oncologist use and perception of large panel next-generation tumor sequencingA M Schram, D Reales, J Galle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2026
Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II TrialJames M Cleary, Christoph Springfeld, Dirk Arnold, et al.
JAMA Oncology|November 17, 2022
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled TrialTimothy A Yap, Aditya Bardia, Michael Dvorkin, et al.
Pageof 19

Showing results (61-70 of 186) with videos related to

Sort By:
Pageof 19
Clinical Genitourinary Cancer|June 1, 2017
Genomic Characterization of Renal Medullary Carcinoma and Treatment OutcomesMaria I Carlo, Joshua Chaim, Sujata Patil, et al.
Future Oncology (London, England)|February 13, 2024
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring <i>NRG1</i> gene fusionsDong-Wan Kim, Alison M Schram, Antoine Hollebecque, et al.
Molecular Cancer Therapeutics|March 5, 2022
CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 HeterodimerizationLisa Werr, Dennis Plenker, Marcel A Dammert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2019
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation BurdenRyma Benayed, Michael Offin, Kerry Mullaney, et al.
Nature Communications|November 23, 2022
Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologiesYonina R Murciano-Goroff, Alison M Schram, Ezra Y Rosen, et al.
Cancer Research|January 16, 2019
Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase FusionsEmiliano Cocco, Jamal Benhamida, Sumit Middha, et al.
The New England Journal of Medicine|February 25, 2026
Phase 1 Study of Rezatapopt, a p53 Reactivator, in <i>TP53</i> Y220C-Mutated TumorsEcaterina E Dumbrava, Geoffrey I Shapiro, Aparna R Parikh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Oncologist use and perception of large panel next-generation tumor sequencingA M Schram, D Reales, J Galle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2026
Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II TrialJames M Cleary, Christoph Springfeld, Dirk Arnold, et al.
JAMA Oncology|November 17, 2022
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled TrialTimothy A Yap, Aditya Bardia, Michael Dvorkin, et al.
Pageof 19